www.cobroxin.com/details.php
Cobroxin is the first over-the-counter pain reliever clinically proven to treat various levels of chronic pain associated with lower back pain, shoulder pain, cramps, migraines, neuralgia and arthritis. Learn More
Cobroxin is aimed at treating all levels of chronic pain. Using a pain scale of 1 to 10, Cobroxin may be used to treat pain in the range of 2-6. Moderate pain is defined as pain that interferes with sleep or work. Severe pain interferes with all activities (7-10) when a physician should be consulted.
Cobroxin is specifically indicated to treat pain associated with: lower back pain, shoulder pain, cramps, migraines and neuralgia. Clinical experience shows that Cobroxin may also provide relief from other forms of pain such as arthritis and the pain associated with cancer. Learn more about the history of Cobroxin.
Cobroxin wins "Best New Product
Nutra Pharma's Recently Launched Pain Reliever, Cobroxin, Wins "Best New Product" Award at Retailing Conference August 31, 2009
Cobroxin, the first clinically proven treatment for Stage 2 (moderate to severe) chronic pain, was selected as the “Best New Product” at the Efficient Collaborative Retail Marketing (ECRM) Conference in Miami, Florida.
Nutra Pharma Corp., a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that its recently launched pain reliever, Cobroxin, was selected as the “Best New Product” at the Efficient Collaborative Retail Marketing (ECRM) Conference. Cobroxin was chosen as the award recipient by conference attendees, including several of the leading national retailers.
“Winning this award is an exciting achievement for Nutra Pharma, as it reflects the significant amount of positive response we have received from retailers who are looking to offer their customers a safe and effective alternative to current pain relievers,” commented Rik J Deitsch, Chairman and CEO of Nutra Pharma. “As we begin introducing Cobroxin through retailers this fall, we plan to continue our efforts educating both retailers and consumers about Cobroxin’s unique analgesic properties, which do not rely on opiates or acetaminophen for its pain relieving effects,” he concluded.
Cobroxin is the first OTC pain reliever clinically proven to treat Stage 2 (moderate to severe) chronic pain. The drug, which was developed by Nutra Pharma’s wholly-owned drug discovery subsidiary, ReceptoPharm, will be available as an oral spray (NDC47219-102-52) for treating lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia and as a topical gel (NDC47219-104-50) for treating repetitive stress, arthritis, and joint pain.
Additional benefits to Cobroxin include:
- All Natural
- Non-Addictive
- Non-Narcotic
- Non-Opiate
- More Potent than Morphine
- Long Lasting
Recently, Nutra Pharma announced a licensing agreement that grants XenaCare Holdings ongoing exclusive marketing and distribution rights for Cobroxin within the United States in return for meeting specific minimum performance requirements. In addition, the Company also announced successful submission of final Cobroxin packaging and labeling to the Food and Drug Administration (FDA), the final step required to begin selling Cobroxin. http://www.nutrapharma.com/newsroom/display.php?newsid=136
ABOUT NUTRAPHARMA (OTCBB:NPHC):
Nutra Pharma Corp. (OTCBB: NPHC) http://www.NutraPharma.com is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases.
Nutra Pharma Corp. through its subsidiaries carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. The Company's holding, ReceptoPharm, Inc., is developing technologies for the production of drugs for HIV and Multiple Sclerosis ("MS"). The Company's subsidiary, Designer Diagnostics, is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Tuberculosis (TB) and Mycobacterium avium-intracellulare (MAI).
Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.
Mission Statement
Nutra Pharma is dedicated to the success of its patients, customers, investors and business partners through its development and acquisition of innovative pharmaceutical and life science solutions that will improve the lives of people throughout the world.
Link to latest presentation given by Rik Dietsch-CEO of Nutra Pharma addressing everything regarding the past, present and future direction of the company, along with an excellent Q&A session at the end: http://a40.video2.blip.tv/5350002509400/Vpoole-NHPCPresentationByCEO594.wmv?bri=11.6&brs=126
All Investors Really Need to see this:
Here is a link to a presentation and Q&A session that Rik Deitsch from Nutra Pharma gave to Norm's conference last week. It is a long presentation with very good information about whats to come as well as a very informative Q&A. ** Required Legal Disclaimer Please be aware that there are forward looking statements provided in this presentation which may or may not pan out. ***
Get ready to Blast off!!! http://a40.video2.blip.tv/5350002509400/Vpoole-NHPCPresentationByCEO594.wmv?bri=11.6&brs=126
Patents
- U.S. Patent No. 5,989,857, which was granted in November 1999 with 10 claims.
- U.S. Patent No. 6,670,148, which was granted in December 2003, with 9 claims. The patent further describes the method for preparing a bioactive peptide (protein) found in cobra venom, in a stable, inactivated form, by treating the peptide with ozone.
- Buccal Delivery System, on which a patent is pending. This application describes a throat spray that permits efficient delivery of the modified peptide drugs to the body through oral mucosa.
- Technology contained in one pending U.S. patent application for the further development of bioactive peptides in cobra venom for use in the treatment of HIV and MS.
- Technology contained in two pending U.S. patent applications for Immunokine Composition and Method, which describes a method for developing modified peptides from alpha-cobratoxin.
- Technology contained in two patents pending for the topical delivery of our proprietary wound healing treatment, which was developed in conjunction with Bio Therapeutics. One of these products is in the form of an ointment style skin protectant and the other a foaming aerosol.
| RECENT NEWS December 07, 2009
Nutra Pharma Completes FDA Submission for Nyloxin OTC and Nyloxin Rx - Over-the-Counter and Prescription Treatments for Chronic Pain
December 03, 2009
Nutra Pharma Announces Upcoming Webinar to Discuss the Company's Over-the-Counter (OTC) and Prescription Treatments for Chronic Pain
November 19, 2009
Nutra Pharma Introduces Chronic Pain Reliever, Nyloxin OTC, for International Distribution
October 22, 2009
Nutra Pharma Announces Publication of Research Report by Cohen Independent Research Group October 14, 2009
Nutra Pharma Announces Online Availability of Cobroxin for the Treatment of Moderate to Severe Chronic Pain October 07, 2009
Nutra Pharma Announces Nyloxin Rx, a Prescription Analgesic for the Treatment of Severe (Stage 3) Chronic Pain October 02, 2009
Nutra Pharma Announces Manufacturing Release of Cobroxin, a Treatment for Chronic Pain |
| August 31, 2009
Nutra Pharma's Recently Launched Pain Reliever, Cobroxin, Wins "Best New Product" Award at Retailing Conference
August 26, 2009
Nutra Pharma Announces Licensing Agreement with XenaCare Holdings to Market and Distribute Cobroxin, a Treatment for Chronic Pain
August 24, 2009
Nutra Pharma Completes FDA Submission for Cobroxin - a Drug for the Treatment of Stage 2 (Moderate to Severe) Chronic Pain
August 20, 2009
Nutra Pharma Announces Launch of Cobroxin, an Over-The-Counter (OTC) Treatment for Stage 2 (Moderate to Severe) Chronic Pain
August 13, 2009
Nutra Pharma Subsidiary, ReceptoPharm, Files Patent Application for the Oral Delivery of Cobra Venom for the Treatment of Pain
June 08, 2009
Nutra Pharma Announces Study Showing RPI-78 More Effective than Morphine in the Treatment of Moderate to Severe Pain
March 26, 2009
Nutra Pharma Subsidiary, ReceptoPharm, Introduces Cost Effective Contract Research Services for Early Stage Life Science Firms
|
Authorized shares as of NOVEMBER 18, 2009: 2,000,000,000
Shares Outstanding as of NOVEMBER 18, 2009: 229,200,232
Float as of NOVEMBER 18, 2009: 148,276,482
Latest 10Q filing - November 18th, 2009 http://www.pinksheets.com/edgar/GetFilingHtml?FilingID=6901938
Wondering what other drug NutraPharma has in the pipeline?
Check out www.receptopharm.com/drug_development/pipeline.php
| Planning | |
| In Progress | |
| Completed | |
Abbreviations: Preclinical (PC), Phase 1 (P-I), Phase 2 (P-II), Phase 3 (P-III)
| | Indication | PC | P-I | P-II | P-III | | | | | | | | | | | | | | | |
| | Indication | Regulatory Status |
| | MODERATE TO SEVERE PAIN (Over-the-Counter) | AVAILABLE NOW! |
www.cobroxin.com/details.php The brand name Nyloxin OTC is the same product as Cobroxin*. Nyloxin RX is the prescription strength available via a Physician only.
*Nyloxin OTC is the brand name NutraPharma will use for all overseas markets while the brand name Cobroxin will be used here in the U.S. Cobroxin is the first over-the-counter pain reliever clinically proven to treat various levels of chronic pain associated with lower back pain, shoulder pain, cramps, migraines, neuralgia and arthritis. Learn More
Nyloxin.com is Now Online www.nyloxin.com/consumers/
Nyloxin RX is a stronger prescription strength version of Cobroxin/Nyloxin OTC
| |
December 07, 2009
|
| |
| Nutra Pharma has completed submission of the final Nyloxin OTC and Nyloxin Rx packaging and labeling to the Food and Drug Administration (FDA). This registration is considered the final step required by the FDA to begin selling Nyloxin OTC and Nyloxin Rx in the United States for the treatment of chronic pain. Nutra Pharma Corp., a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it has successfully submitted the final packaging and labeling to the Food and Drug Administration (FDA) to begin selling Nyloxin OTC, an over-the-counter treatment for moderate to severe (Stage 2) chronic pain, and Nyloxin Rx, a prescription treatment for severe (Stage 3) chronic pain. “Completing the FDA registration for Nyloxin OTC and Nyloxin Rx is an important and required step towards introducing our Nyloxin-branded pain relievers throughout domestic and international markets,” explained Rik J Deitsch, Chairman and CEO of Nutra Pharma. “With the FDA registration now completed, we plan to immediately move forward with our launch of Nyloxin Rx here in the United States, while we finalize our international drug registrations in Canada, Europe and South America for both our prescription and over-the-counter formulations,” he concluded. The Company first introduced Nyloxin OTC in November as a treatment for moderate to severe (Stage 2) chronic pain. Nyloxin OTC is similar to the Company’s recently launched pain reliever, Cobroxin, and will be available internationally as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia and as a topical gel for treating joint pain and pain associated with repetitive stress and arthritis. Additionally, the Company introduced Nyloxin Rx in October as a prescription treatment for severe (Stage 3) chronic pain. Unlike Stage 2 pain, which interferes with both work and sleep, Nyloxin Rx is aimed at treating the most severe pain that inhibits one’s ability to fully function. Both Nyloxin OTC and Nyloxin Rx are produced by Nutra Pharma’s wholly-owned drug discovery subsidiary, ReceptoPharm, and do not rely on the use of opioids or acetaminophen for their pain relieving action. This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). Completing the FDA registration for Nyloxin OTC and Nyloxin Rx should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement. |
- Images from the Cobroxin Bottling Plant
Posted on Jan 24th, 2010 by Corporate Communications Last week, we spent time visiting the Cobroxin bottling facility. While we were there, we took a few photos to share on our blog. We hope you enjoy the following images. 
Most of the packaging process is automated, including the labeling of the bottles. In this photo, you can see the labeling machine printing the labels to go on the Cobroxin Oral Spray bottles. 
At Nutra Pharma, we continually strive to manufacture the highest quality products. In this photo you can see several members of our bottler’s quality assurance team. Their role at the bottling facility is to ensure that every bottle of Cobroxin meets or exceeds our strict quality standards. 
Once the bottles of Cobroxin are filled, labeled and individually shrink wrapped, they are then grouped into cartons containing 12 bottles and placed on pallets for immediate shipment. As you can see from the above photo, we even custom print our shipping cartons to include the Cobroxin logo. For more information about Cobroxin, visit http://www.Cobroxin.com. SEC Disclaimer This article contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The article, "Images from the Cobroxin Bottling Plant", should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement. |
David Isserman
Investor Relations
Toll-Free: (877) 895-5647
investor.relations@nutrapharma.com